Takhzyro (lanadelumab-flyo) is a biologic medicine used to prevent hereditary angioedema (HAE) attacks in people who are 2 years or older. During an HAE attack, swelling under the skin happens in ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European ...

The EC’s approval was based on results from the phase 3 OASIS-HAE study. The study showed that an 80mg dose of Dawnzera every ...

After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

Ionis IONS and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...

The goal of acute treatment of an hereditary angioedema (HAE) attack is to reduce its duration and severity and thus limit its impact on the patient’s functional ability and prevent a potentially ...

Otsuka’s Dawnzera is now approved in the EU to prevent hereditary angioedema attacks in patients 12 and older, offering a ...

Like angioedema in general, hereditary angioedema (HAE) is characterized by subcutaneous or submucosal edema that is nonpruritic — ie, does not itch — and nonpitting — ie, does not leave an ...

Otsuka Pharmaceutical, which licensed the antisense oligonucleotide from Ionis, has rights to commercialize it in Europe and Asia.

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of ...

Good day and thank you for standing by. Welcome to the RAPIDe-3 topline data webcast. [Operator Instructions] I would now like to hand the conference over to your speaker, Maggie, please go ahead.